Taiwan starts clinical trials of remdesivir on COVID-19 patients

Focus Taiwan
Date: 03/19/2020
By: Chang Min-hsuan, Chen Yi-hsuan and Ko Lin

Image taken from Pixabay for illustrative purposes only

Taipei, March 19 (CNA) Clinical trials of the antiviral drug remdesivir for the treatment of the coronavirus disease COVID-19 have already started in Taiwan, Central Epidemic Command Center (CECC) expert Chang Shang-chun (張上淳) said Thursday.

Speaking at a daily CECC briefing in Taipei, Chang said remdesivir is a highly anticipated drug that many believe could be a potential treatment for COVID-19 patients.

Originally developed by the American drugmaker Gilead Sciences for use against the Ebola virus, remdesivir has been widely discussed as a possible coronavirus treatment, following positive results from Chinese and American doctors who have administered the drug experimentally.

On Jan. 31, Gilead said in a statement that it was working with the Chinese authorities to conduct a clinical trial involving the use of remdesivir on coronavirus patients.   [FULL  STORY]

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy

This site uses Akismet to reduce spam. Learn how your comment data is processed.